Núñez-Gil IJ, Olier I, Feltes G, et al. - Because Renin-Angiotensin system inhibitors (RASi) use in coronavirus disease 2019 (COVID-19) cases has been questioned as both share a target receptor site, therefore, researchers analyzed patients discharged following an in-hospital stay with COVID-19, dead or alive, to determine the influence of previous as well as continued in-hospital treatment with RASi on all-cause mortality and the occurrence of in-stay complications. They used an international investigator-initiated registry (HOPE-COVID-19). According to findings, RASi historic use, at admission, was not associated with an adjusted worse prognosis in COVID-19 patients who were hospitalized, although it highlights a high-risk group. In this setting, improved survival as well as fewer short-term complications were reported in relation to in-hospital prescription of RASi.